| タイトル |
-
Effective SGLT2 Inhibitor for Patient with Type 2 Diabetes Mellitus (T2DM) and Depression
|
| 作成者 |
|
| 権利情報 |
-
© 2020 Shimizu E, Takehisa Y, Bando H, Fujita M, Kusaka Y, Yuu M. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
| 主題 |
-
Other
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor
-
Other
Ipragliflozin L-Proline
-
Other
Depression
-
Other
Oral Hypoglycemic Agents (OHA)
-
Other
Low-Carbohydrate Diet (LCD)
|
| 内容注記 |
-
Other
The case was a 55-year-old female patient with depression for 5 years and type 2 diabetes mellitus (T2DM) for 3 years. She has received anti-depressant and anti-hyperglycemic agents (OHAs). Approximately 1 year ago, her diabetic control became exacerbated without specific triggers. She was started to given Ipragliflozin L-Proline as Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. After that, her glucose variability and depression had been improved. According to the previous reports, SGLT-2 inhibitors seem to have anti-depression efficacy for diabetes. The case has been followed up in detail, and this report is expected to be a useful reference for diabetes care.
|
| 出版者 |
Asploro
|
| 日付 |
|
| 言語 |
|
| 資源タイプ |
journal article |
| 出版タイプ |
VoR |
| 資源識別子 |
URI
http://repo.lib.tokushima-u.ac.jp/114810
|
| 関連 |
-
isIdenticalTo
DOI
https://doi.org/10.36502/2020/droa.6160
|
| 収録誌情報 |
-
Diabetes Research : Open Access
-
巻2
号S1
開始ページ26
終了ページ32
|
| ファイル |
|
| コンテンツ更新日時 |
2023-06-26 |
